Does surgery spread pancreatic cancer? new study investigates
NCT ID NCT03435536
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at 35 people having surgery for pancreatic cancer to see if moving the tumor during the operation causes more cancer DNA to enter the bloodstream. Researchers took blood samples before, during, and after surgery to track these DNA levels. The goal was to better understand how surgery might affect cancer spread, not to test a new treatment.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this could help doctors understand if surgery itself causes cancer cells to spread, potentially leading to better surgical techniques or monitoring strategies.
- What could go wrong
- This is a very small, early pilot study with only 35 participants. It is designed to gather information, not to test a treatment, so it may not lead to any direct changes in patient care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
35 people
The number who actually took part.
- Started
-
Feb 2018
- Finished
-
Jun 2022
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Every patient taken care by Toulouse University Hospital for the resection of a non-metastatic pancreatic adenocarcinoma by whipple resection. * Patient aged over 18 years old * Patient having given his written consent * Patient with social insurance coverage Exclusion Criteria: * Patients who had surgery, but their pathological examination of the resected specimen does not contain adenocarcinoma. * Patient for whom the surgery was not realized (exploratory laparotomy)
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Resectable pancreatic adenocarcinoma are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University Hospital
Toulouse, 31059, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Scientists hunt for clues to prevent a common complication after pancreatic cancer surgery
- Pancreatic cancer showdown: surgery first or chemo first?
- Timing of chemo may boost survival in pancreatic cancer
- New chemo cocktail shows promise for pancreatic cancer patients before surgery
- New drug cocktail shows promise against tough pancreatic cancer
- Electric field therapy + chemo shows promise against pancreatic cancer